Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy
Study Details
Study Description
Brief Summary
This is a prospective, observational study to collect stool and blood from acute myeloid leukemia patients undergoing intensive chemotherapy.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Abundance of Phyla [Day 28]
Abundance in stool and circulating microbiota during intensive chemotherapy in patients with acute myeloid leukemia (AML), measured by16S rRNA gene profiling of biospecimens using the Illumina MiSeq platform
- Abundance of Genera [Day 28]
Abundance in stool and circulating microbiota during intensive chemotherapy in patients with acute myeloid leukemia (AML), measured by16S rRNA gene profiling of biospecimens using the Illumina MiSeq platform
Secondary Outcome Measures
- Circulating Microbiota Diversity (Blood) [Day 28]
Describe circulating microbiota diversity over the course of treatment
- Microbiota Diversity (Stool) [Day 28]
Describe stool microbiota diversity over the course of treatment
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adults (ages 18 - 99 years) undergoing inpatient intensive chemotherapy for newly diagnosed, refractory, or relapsed AML. Patients may or may not have been exposed to any type of therapy before.
-
Any intensive chemotherapy regimen defined as a planned ~4 week inpatient stay. Chemotherapy may be delivered for any number of days and on any schedule. Patients may be discharged from the hospital sooner than 4 weeks if the treating physician choose so, but the expectation at the initiation of chemotherapy must be ~4 weeks of inpatient stay, as is typical.
-
Able to provide written voluntary consent before performance of any study related procedure.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Masonic Cancer Center at University of Minnesota | Minneapolis | Minnesota | United States | 55455 |
Sponsors and Collaborators
- Masonic Cancer Center, University of Minnesota
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2018NTLS107
- HM2018-23